skip to Main Content


PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
The company is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.

XEN-D0501 is a synthetic small molecule that was in-licensed in 2016.
Prior to in-licensing, XEN-D0501 had been found to have a good safety profile in other (non-diabetic) patient groups.

PILA PHARMA has to date completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes.

Further, PP-CT02, demonstrated that XEN-D0501 (administered as 4 mg BID for 28 days) – with statistical significance versus placebo – enhance the endogenous insulin response to oral glucose.



We’ve been interviewed about our background and our intentions to list PILA PHARMA AB later this year.

Please, read the article by Biostock (in Swedish) here


We’re delighted to be the cover of this collection of CEO interviews!

Read the Swedish Health Care Sector Analysis distributed with Dagens Industri here
Read the article about Pila Pharma (in Swedish) here


Video interview (in Swedish) with CEO Dorte X. Gram by ‘Invest Talks’

Watch the interview in Swedish here

Pila Pharma Press releases

PILA PHARMA announces successful completion of Pre-IPO

Read the Press release here


Development of a novel drug to treat diabetes.
Investor presentation by CEO Dorte X. Gram at the BioStock Life Science Summit 2020, Lund, Sweden.

Watch the presentation in English here


The Malmö-based company Pila Pharma, which has a drug candidate for type 2 diabetes, will be listed on one of the Swedish stock exchanges in the second quarter of next year.

Read the article in Swedish here


Pila Pharma has scheduled its arrival on the Swedish stock market for May next year with the goal of fetching SEK 50m for developing the firm’s diabetes tablet leading up to phase III.

An interview with CEO Dorte X. Gram by Medwatch, Denmark.
Read the article in English here
Read the article in Danish here


Our Opinion and Concept Paper on the role of TRPV1 in diabetes published in Trends in Molecular Medicine.

Read the paper here

PILA PHARMA AB has been selected to be 1 of 200 SMEs to receive an SME Instrument Phase 1 grant (EUR 50 000).

Read the general EU announcement here and the project abstract here

Back To Top